203 related articles for article (PubMed ID: 38622715)
1. Multi-omics and immunogenomics analysis revealed PFKFB3 as a targetable hallmark and mediates sunitinib resistance in papillary renal cell carcinoma: in silico study with laboratory verification.
Lu Z; Pan Y; Wang S; Wu J; Miao C; Wang Z
Eur J Med Res; 2024 Apr; 29(1):236. PubMed ID: 38622715
[TBL] [Abstract][Full Text] [Related]
2. Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.
Tang Q; Pan D; Xu C; Chen L
J Cancer Res Clin Oncol; 2023 Jan; 149(1):231-245. PubMed ID: 36404389
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of PFKFB3 promotes cell glycolysis and proliferation in renal cell carcinoma.
Li J; Zhang S; Liao D; Zhang Q; Chen C; Yang X; Jiang D; Pang J
BMC Cancer; 2022 Jan; 22(1):83. PubMed ID: 35057732
[TBL] [Abstract][Full Text] [Related]
4. Glycolytic regulatory enzyme PFKFB3 as a prognostic and tumor microenvironment biomarker in human cancers.
Da Q; Huang L; Huang C; Chen Z; Jiang Z; Huang F; Shen T; Sun L; Yan Z; Ye X; Yi J; Huang Y; Da J; Ren M; Liu J; Wang T; Han Z; Ouyang K
Aging (Albany NY); 2023 May; 15(10):4533-4559. PubMed ID: 37253634
[TBL] [Abstract][Full Text] [Related]
5. PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance.
Feng C; Li Y; Li K; Lyu Y; Zhu W; Jiang H; Wen H
J Exp Clin Cancer Res; 2021 Sep; 40(1):308. PubMed ID: 34593007
[TBL] [Abstract][Full Text] [Related]
6. The effect of a novel glycolysis-related gene signature on progression, prognosis and immune microenvironment of renal cell carcinoma.
Xu F; Guan Y; Xue L; Huang S; Gao K; Yang Z; Chong T
BMC Cancer; 2020 Dec; 20(1):1207. PubMed ID: 33287763
[TBL] [Abstract][Full Text] [Related]
7. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
[TBL] [Abstract][Full Text] [Related]
8. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
[No Abstract] [Full Text] [Related]
9. Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.
Saleeb RM; Farag M; Lichner Z; Brimo F; Bartlett J; Bjarnason G; Finelli A; Rontondo F; Downes MR; Yousef GM
Mol Oncol; 2018 Oct; 12(10):1673-1688. PubMed ID: 29896907
[TBL] [Abstract][Full Text] [Related]
10. Combination of 3PO analog PFK15 and siPFKL efficiently suppresses the migration, colony formation ability, and PFK-1 activity of triple-negative breast cancers by reducing the glycolysis.
Kashyap A; Umar SM; Dev J R A; Mathur SR; Gogia A; Batra A; Deo SVS; Prasad CP
J Cell Biochem; 2023 Sep; 124(9):1259-1272. PubMed ID: 37450687
[TBL] [Abstract][Full Text] [Related]
11. Identification of 4-genes model in papillary renal cell tumor microenvironment based on comprehensive analysis.
Luo L; Zhou H; Su H
BMC Cancer; 2021 May; 21(1):553. PubMed ID: 33993869
[TBL] [Abstract][Full Text] [Related]
12. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
13. A five-gene signature may predict sunitinib sensitivity and serve as prognostic biomarkers for renal cell carcinoma.
Chen YL; Ge GJ; Qi C; Wang H; Wang HL; Li LY; Li GH; Xia LQ
J Cell Physiol; 2018 Oct; 233(10):6649-6660. PubMed ID: 29327492
[TBL] [Abstract][Full Text] [Related]
14. Key sunitinib-related biomarkers for renal cell carcinoma.
Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
[TBL] [Abstract][Full Text] [Related]
15. Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis.
Wang Y; Yan K; Lin J; Wang J; Zheng Z; Li X; Hua Z; Bu Y; Shi J; Sun S; Li X; Liu Y; Bi J
Aging (Albany NY); 2020 Nov; 12(21):21854-21873. PubMed ID: 33154194
[TBL] [Abstract][Full Text] [Related]
16. Identification of potential biomarkers associated with immune infiltration in papillary renal cell carcinoma.
Deng R; Li J; Zhao H; Zou Z; Man J; Cao J; Yang L
J Clin Lab Anal; 2021 Nov; 35(11):e24022. PubMed ID: 34606125
[TBL] [Abstract][Full Text] [Related]
17. Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor.
Zhang H; Bai L; Wu XQ; Tian X; Feng J; Wu X; Shi GH; Pei X; Lyu J; Yang G; Liu Y; Xu W; Anwaier A; Zhu Y; Cao DL; Xu F; Wang Y; Gan HL; Sun MH; Zhao JY; Qu Y; Ye D; Ding C
Nat Commun; 2023 Jul; 14(1):4274. PubMed ID: 37460463
[TBL] [Abstract][Full Text] [Related]
18. Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways.
Xie Y; Shangguan W; Chen Z; Zheng Z; Chen Y; Zhong Q; Zhang Y; Yang J; Zhu D; Xie W
Drug Des Devel Ther; 2021; 15():5061-5074. PubMed ID: 34938069
[TBL] [Abstract][Full Text] [Related]
19. Screening and identification of key biomarkers of papillary renal cell carcinoma by bioinformatic analysis.
Xu Y; Kong D; Li Z; Qian L; Li J; Zou C
PLoS One; 2021; 16(8):e0254868. PubMed ID: 34358255
[TBL] [Abstract][Full Text] [Related]
20. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
